EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische StudieOpen Access · CC BY 4.0

Safety and Efficacy of a 24‐Cycle Administration of a Drospirenone‐Only Pill in Japanese Women

Kunio Kitamura, Enrico Colli, Ryoko Kikuyama, Yumiko Kurihara, Rieko Azuma, Tomoya Kagawa

Journal of Obstetrics and Gynaecology Research · 2026

DOI: 10.1111/jog.70309 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2026. Verfasst von Kunio Kitamura und 5 weiteren Autor:innen. Beteiligte Einrichtung: Japan Family Planning Association, Tokyo, Japan. Hauptthemen laut MEDLINE: Androstenes. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ASKA Pharmaceutical Co. Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

We conducted a 24‐cycle study to evaluate long‐term safety of 4 mg of drospirenone (DRSP), a progestin‐only pill (POP), for contraception in Japanese women.

Methods

A multicenter, single‐arm 24‐cycle study was conducted in women who participated in the 13 cycle study of DRSP. In each cycle, 4 mg of DRSP tablet was administered orally once daily for 24 consecutive days, followed by a placebo tablet for 4 days.

Results

In this 24‐cycle study, the total number of DRSP exposure cycles was 3878. Fifty‐two subjects (100.0%) experienced treatment‐emergent adverse events (TEAEs), and 50 (96.2%) experienced adverse drug reactions. All TEAEs were mild or moderate with no severe events. The most common TEAE was intermenstrual bleeding, which occurred in 49 (94.2%) subjects. Although 50.0% of the subjects had risk factors for venous thromboembolism (VTE), no VTE‐related TEAEs were observed. No TEAEs led to discontinuation of the study. During 3878 exposure cycles, pregnancy occurred in one subject. The overall Pearl index [95% CI] was 0.34 [0.01, 1.87], and the cumulative pregnancy rate was 0.4%.

Conclusions

In this study, the safety of DRSP, the first POP in Japan, was evaluated in Japanese women for 24 cycles. The DRSP‐only pill provides a new option for contraception for Japanese women, including those at risk of developing VTE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AndrostenesHumansFemaleAdultJapanYoung AdultPregnancyEast Asian People

Stichwörter der Autor:innen

contraceptiondrospirenoneoral contraceptivesprogestinsafety

Substanzen

Androstenesdrospirenone

Autor:innen und Institutionen

  • Japan Family Planning Association, Tokyo, Japan.
  • Exeltis, Madrid, Spain.
  • ASKA Pharmaceutical Co., Ltd, Tokyo, Japan.

Förderung

  • ASKA Pharmaceutical Co. Ltd

Zitieren

APA

Kitamura, K., Colli, E., Kikuyama, R., Kurihara, Y., Azuma, R., & Kagawa, T. (2026). Safety and Efficacy of a 24‐Cycle Administration of a Drospirenone‐Only Pill in Japanese Women. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.70309

Vancouver

Kitamura K, Colli E, Kikuyama R, Kurihara Y, Azuma R, Kagawa T. Safety and Efficacy of a 24‐Cycle Administration of a Drospirenone‐Only Pill in Japanese Women. Journal of Obstetrics and Gynaecology Research. 2026. doi:10.1111/jog.70309

BibTeX
@article{Kitamura2026,
  author = {Kitamura, Kunio and Colli, Enrico and Kikuyama, Ryoko and Kurihara, Yumiko and Azuma, Rieko and Kagawa, Tomoya},
  title = {Safety and Efficacy of a 24‐Cycle Administration of a Drospirenone‐Only Pill in Japanese Women},
  journal = {Journal of Obstetrics and Gynaecology Research},
  year = {2026},
  doi = {10.1111/jog.70309}
}
Kostenlos starten →